Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
399 Binney Street, 2 Nd Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 26, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.75K % +13.3%
Debt-to-equity 12.2 % -25.3%
Return On Equity -44.4 % -4.57%
Return On Assets -39.6 % -8.45%
Operating Margin -1.03K % +96.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 170M shares +27.7%
Common Stock, Shares, Outstanding 168M shares +31.6%
Entity Public Float 859M USD -42.7%
Common Stock, Value, Issued 168K USD +32.3%
Weighted Average Number of Shares Outstanding, Basic 143M shares +16.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35.3M USD +2874%
Revenue from Contract with Customer, Excluding Assessed Tax 35.3M USD +2874%
General and Administrative Expense 76.6M USD +2.19%
Operating Income (Loss) -372M USD +0.14%
Net Income (Loss) Attributable to Parent -338M USD +1.25%
Earnings Per Share, Basic -2.36 USD/shares +15.4%
Earnings Per Share, Diluted -2.36 USD/shares +15.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 124M USD -13.5%
Accounts Receivable, after Allowance for Credit Loss, Current 211K USD -12.4%
Other Assets, Current 10.5M USD +218%
Assets, Current 809M USD +5.08%
Property, Plant and Equipment, Net 5.91M USD -45.8%
Operating Lease, Right-of-Use Asset 51.8M USD -10.7%
Assets 871M USD +3.24%
Accounts Payable, Current 14.1M USD +53%
Accrued Liabilities, Current 21.2M USD +42.6%
Liabilities, Current 50.7M USD +67.6%
Operating Lease, Liability, Noncurrent 42.8M USD -11.8%
Liabilities 93.5M USD +1.66%
Accumulated Other Comprehensive Income (Loss), Net of Tax -991K USD -406%
Retained Earnings (Accumulated Deficit) -1.74B USD -24.1%
Stockholders' Equity Attributable to Parent 778M USD +3.43%
Liabilities and Equity 871M USD +3.24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.3M USD +25%
Net Cash Provided by (Used in) Financing Activities 48.9M USD +3672%
Net Cash Provided by (Used in) Investing Activities 10.5M USD -86%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 168M shares +31.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.13M USD -3.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 126M USD -13.7%
Deferred Tax Assets, Valuation Allowance 432M USD +44.1%
Deferred Tax Assets, Gross 446M USD +42.8%
Depreciation 1.4M USD +16.5%
Payments to Acquire Property, Plant, and Equipment 1.78M USD -7.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -339M USD -2.04%
Property, Plant and Equipment, Gross 34.8M USD +0.99%
Operating Lease, Liability, Current 5.73M USD +15.4%
Deferred Tax Assets, Operating Loss Carryforwards 166M USD +17.6%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 2.52B USD +16.9%
Deferred Tax Assets, Net of Valuation Allowance 13.9M USD +13.2%
Share-based Payment Arrangement, Expense 94.1M USD +9.43%